BioMedNewsBreaks Archive - Page 47 of 241

TuesdayOct 22, 2024 9:00 am

BioMedNewsBreaks – HealthLynked Corp. (OTC: HLYK) Partners With 3X4 Genetics to Enhance Personalized Healthcare Services

HealthLynked Corp. (OTCQB: HLYK) has announced a strategic partnership with 3X4 Genetics to offer personalized genetic testing to its members, advancing its mission to provide tailored and predictive healthcare solutions. The collaboration will allow HealthLynked members to access 3X4 Genetics' sophisticated genetic insights, empowering them to make informed health decisions and receive more personalized care. This partnership marks a key step in HealthLynked's broader strategy of integrating cutting-edge technologies to improve healthcare outcomes and expand its service offerings. To view the full press release, visit https://ibn.fm/GL0d6 About HealthLynked Corp. HealthLynked Corp. is committed to improving global healthcare by facilitating the…

TuesdayOct 15, 2024 1:54 pm

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance for Pivotal Phase 3 Alzheimer’s Trial, Launch Set for Early 2025

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), announced today that the U.S. Food and Drug Administration (“FDA”) has granted clearance to proceed with pivotal Phase 3 studies for buntanetap in early-stage Alzheimer’s patients. This decision follows a successful End-of-Phase 2 meeting held on Oct. 10, 2024, where Annovis and the FDA aligned on the next steps for advancing buntanetap toward New Drug Application (“NDA”) submissions. The Phase 3 program will consist of two trials: a 6-month study aimed at confirming…

TuesdayOct 15, 2024 10:15 am

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Files Patent for ‘Gamechanging’ AI-Powered Healthcare Assistant

HealthLynked (OTCQB: HLYK), a leader in connecting patients, doctors and healthcare data, has filed a patent with the United States Patent and Trademark Office (“USPTO”). According to the announcement, the nonprovisional patent covers ARi, an innovative artificial intelligence (“AI”)-powered personal healthcare assistant and is designed to provide long-term protection for Ari and the company. HealthLynked noted that last year it filed a provisional patent following the release of Generative Pretrained Transformers (“GPT”) and Large Language Models (“LLMs”) from OpenAI. “At HealthLynked, we are committed to empowering patients to take control of their health,” said HealthLynked CEO Dr. Michael Dent in…

MondayOct 14, 2024 3:40 pm

BioMedNewsBreaks — Astiva Health Providing Standout Option During Medicare Open Enrollment Period

Astiva is a leading provider of personalized and comprehensive healthcare solutions to diverse communities. “Medicare open enrollment for 2024-2025 begins on Oct. 15, 2024, and closes on Dec. 7, 2024, as noted in a recent Medicare Advocates article… Astiva Health provides a standout option during this critical enrollment period, offering a health plan designed to meet the specialized needs of its members,” a recent article reads. “A key feature of Astiva’s plans is its unmatched rebates and grocery benefits. Members are eligible to receive the full Part B premium rebate of $174.70 monthly, helping to alleviate the financial burden of healthcare…

ThursdayOct 10, 2024 1:08 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company announced Thursday morning that it participated in a Virtual Investor KOL Connect segment. Members of the company’s management team and Dr. Samuel Goldlust, who previously served as an investigator in the company’s global potentially pivotal study of Berubicin, joined the segment to provide a corporate update, discuss the unmet need in glioblastoma multiforme (“GBM”), and highlight the opportunity for the company. To access the segment, visit https://ibn.fm/V1eC1 To view the full…

WednesdayOct 09, 2024 1:35 pm

BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment

Oragenics (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, has released a corporate update. Highlights of shareholder report include an overview of key milestones reached this year as the company has developed its lead candidate, ONP-002, a first-in-class neurosteroid designed for the treatment of concussions. Those milestones include strengthening the company’s clinical leadership, preparing for a phase 2 clinical trial, successful cardiotoxicity testing and required genotoxicity studies and establishing a key partnership with Avance Clinical, a leading contract research organization (“CRO”). “Our mission is to address significant unmet medical needs by developing cutting-edge therapies,”…

TuesdayOct 08, 2024 12:30 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Fireside Chat at 2024 Healthcare Virtual Summit

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming 2024 Healthcare Virtual Summit. The summit, which is presented by Maxim Group LLC, is scheduled for Oct. 16, 2024. According to the announcement, CNS Pharmaceuticals CEO John Climaco will be part of a fireside chat, slated to begin at 4 p.m. ET during the one-day event. In addition to the fireside chat, the summit will include presentations, interactive discussions and topical industry panels with an array of biotechnology,…

MondayOct 07, 2024 2:34 pm

BioMedNewsBreaks — Roth Capital Partners with IBN as Official Media Sponsor of Annual Roth Healthcare Opportunities Conference

Roth Capital Partners (Roth MKM), a relationship-driven investment bank dedicated to serving growth companies and their investors, is partnering with IBN as an official media sponsor for this week’s third annual Roth Healthcare Opportunities Conference. The invitation-only, one-day conference is scheduled for Oct. 9, 2024, in New York City. According to the announcement, IBN will leverage its extensive corporate communications network to increase awareness of the conference, which is an exclusive platform that gathers together veteran investors with C-suite executives from public and private companies in the healthcare sector. “ROTH's upcoming conference is set to showcase some of the most…

MondayOct 07, 2024 10:55 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Announces ‘Significant’ Extension and Expansion of Exclusive Distribution Agreement with OPKO Health

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that its original exclusive e-commerce distribution contract with OPKO Health Inc. (NASDAQ: OPK) has been extended for four years and expanded to include additional e-commerce platforms and digital and social media marketing across China. The original agreement allowed NextPlat to sell OPKO Health Europe’s nutraceutical and veterinary products on the Tmall Global e-commerce platform only. According to the announcement, the expanded contract also grants NextPlat the exclusive rights to sell and market OPKO products in Japan. “The significant extension and expansion of our agreement with OPKO is evidence of the…

ThursdayOct 03, 2024 2:30 pm

BioMedNewsBreaks — 180 Life Sciences Corp. (NASDAQ: ATNF) Provides Update on Strategic Corporate Initiatives

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released an update on several key initiatives, including announcing the acquisition of an advanced Gaming Technology Platform, positive progress on its Legacy CBD formulation and a strengthened balance sheet. According to the update, the company is shifting its focus as it enters the global iGaming market through its acquisition of a comprehensive intellectual property package, consisting of a complete back-end technology solution for online casino operations. In addition, the company anticipates retaining its current portfolio of biotechnology intellectual property as it reports positive study results exhibiting faster absorption and improved…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – HealthLynked Corp. (OTC: HLYK) Partners With 3X4 Genetics to Enhance Personalized Healthcare Services

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives FDA Clearance for Pivotal Phase 3 Alzheimer’s Trial, Launch Set for Early 2025

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Files Patent for ‘Gamechanging’ AI-Powered Healthcare Assistant

BioMedNewsBreaks — Astiva Health Providing Standout Option During Medicare Open Enrollment Period

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Management, Dr. Samuel Goldlust Participate in Virtual Investor KOL Connect Segment

BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Fireside Chat at 2024 Healthcare Virtual Summit

BioMedNewsBreaks — Roth Capital Partners with IBN as Official Media Sponsor of Annual Roth Healthcare Opportunities Conference

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Announces ‘Significant’ Extension and Expansion of Exclusive Distribution Agreement with OPKO Health

BioMedNewsBreaks — 180 Life Sciences Corp. (NASDAQ: ATNF) Provides Update on Strategic Corporate Initiatives

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search